Patients with advanced melanoma often experience durable tumor regressions when they are reinfused with culture-expanded natural T-cells derived from their own tumor nodules, in conjunction with nonmyeloablative chemotherapy and high dose IL-2 [1, 2]. Here, IL2 is linked to melanoma.